Mildred Sergon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mildred Sergon has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Achim Hekler
Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany
3 shared publicationsChristof von Kalle
Department of Clinical-Translational Sciences, Charité University Medicine and Berlin Institute of Health (BIH), Berlin, Germany
3 shared publications- Daniel B. Lipka
Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center, Heidelberg, Germany
3 shared publications Dirk Schadendorf
Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany
3 shared publications- Friedegund Meier
Department of Dermatology, Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01062 Dresden, Germany
3 shared publications - Gabriela Poch
Department of Dermatology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
3 shared publications
Latest Publications
- Open Access
- 16 October 2023
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 1166-1171
Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of 177Lu-DOTATATE therapy, targeted alpha-particle therapy (TAT) may be a possible treatment option. Here, we present a patient with cancer of unknown primary NET G2 later G3. The patient was referred to our hospital with urosepsis due to a second-degree urinary retention. After stent insertion, a contrast-enhanced computed tomography revealed a huge pelvic tumor without metastases. Initially, the patient had undergone surgical treatment. Later the patient developed liver metastasis and was treated by 177Lu-DOTATATE therapy and four lines of systemic therapy. A disease progression was observed and with the knowledge of a germline BRCA1 mutation, the patient was treated with TAT (Actinium-225 [225Ac]-DOTATATE) combined with olaparib. The patient achieved a significant treatment response for 12 months indicating that a combination therapy with an alpha emitter and olaparib demands further investigations in clinical trials.
- 16 October 2023
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 1166-1171
Open AccessSuccessful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (177Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of 177Lu-DOTATATE therapy, targeted alpha-particle therapy (TAT) may be a possible treatment option. Here, we present a patient with cancer of unknown primary NET G2 later G3. The patient was referred to our hospital with urosepsis due to a second-degree urinary retention. After stent insertion, a contrast-enhanced computed tomography revealed a huge pelvic tumor without metastases. Initially, the patient had undergone surgical treatment. Later the patient developed liver metastasis and was treated by 177Lu-DOTATATE therapy and four lines of systemic therapy. A disease progression was observed and with the knowledge of a germline BRCA1 mutation, the patient was treated with TAT (Actinium-225 [225Ac]-DOTATATE) combined with olaparib. The patient achieved a significant treatment response for 12 months indicating that a combination therapy with an alpha emitter and olaparib demands further investigations in clinical trials.
- Open Access
- 13 August 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 173, 307-316
Model soups improve performance of dermoscopic skin cancer classifiers
- 13 August 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 173, 307-316
Open AccessModel soups improve performance of dermoscopic skin cancer classifiers
- Top Cited PapersOpen Access
- 5 April 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 167, 54-69
Explainable artificial intelligence in skin cancer recognition: A systematic review
- 5 April 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 167, 54-69
Top Cited PapersOpen AccessExplainable artificial intelligence in skin cancer recognition: A systematic review
- Top Cited PapersOpen Access
- 1 October 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 156, 202-216
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts
- 1 October 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 156, 202-216
Top Cited PapersOpen AccessSkin cancer classification via convolutional neural networks: systematic review of studies involving human experts
- Open Access
- 29 June 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1186-1199
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*
Background Eccrine porocarcinoma (EPC) is a rare skin cancer arising from the eccrine sweat glands. Due to the lack of effective therapies, metastasis is associated with a high mortality rate. Objectives To investigate drivers of EPC progression. Methods Here, we report the genomic and transcriptomic profiling of mEPC, validation of the observed alterations in an EPC patient-derived cell line, confirmation of relevant observations in a large patient cohort of 30 tumour tissues and successful treatment of a mEPC patient with the identified treatment regimes. Results mEPC was characterized by a high tumour mutational burden with a UV-signature, widespread copy number alterations and gene expression changes that affected cancer-relevant cellular processes like cell cycle regulation and proliferation, including a pathogenic TP53 mutation, a copy number deletion in the CDKN2A region and a CTNND1-PAK1 fusion. The overexpression of EGFR, PAK1, and MAP2K1 (MEK1) genes translated into strong protein expression and respective pathway activation in the tumour tissue. Furthermore, a patient-derived cell line was sensitive to EGFR and MEK inhibition, confirming the functional relevance of the pathway activation. Immunohistochemistry analyses in a large patient cohort showed the relevance of the observed changes to the pathogenesis of EPC. Our results indicate that mEPC should respond to immune or kinase inhibitor therapy. Indeed, the advanced disease of our index patient was controlled by EGFR-directed therapy and immune checkpoint inhibition for more than 2 years. Conclusions Molecular profiling demonstrated high tumour mutational burden and EGFR/MAPK pathway activation as novel therapeutic targets in mEPC.
- 29 June 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1186-1199
Open AccessHigh tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*
Background Eccrine porocarcinoma (EPC) is a rare skin cancer arising from the eccrine sweat glands. Due to the lack of effective therapies, metastasis is associated with a high mortality rate. Objectives To investigate drivers of EPC progression. Methods Here, we report the genomic and transcriptomic profiling of mEPC, validation of the observed alterations in an EPC patient-derived cell line, confirmation of relevant observations in a large patient cohort of 30 tumour tissues and successful treatment of a mEPC patient with the identified treatment regimes. Results mEPC was characterized by a high tumour mutational burden with a UV-signature, widespread copy number alterations and gene expression changes that affected cancer-relevant cellular processes like cell cycle regulation and proliferation, including a pathogenic TP53 mutation, a copy number deletion in the CDKN2A region and a CTNND1-PAK1 fusion. The overexpression of EGFR, PAK1, and MAP2K1 (MEK1) genes translated into strong protein expression and respective pathway activation in the tumour tissue. Furthermore, a patient-derived cell line was sensitive to EGFR and MEK inhibition, confirming the functional relevance of the pathway activation. Immunohistochemistry analyses in a large patient cohort showed the relevance of the observed changes to the pathogenesis of EPC. Our results indicate that mEPC should respond to immune or kinase inhibitor therapy. Indeed, the advanced disease of our index patient was controlled by EGFR-directed therapy and immune checkpoint inhibition for more than 2 years. Conclusions Molecular profiling demonstrated high tumour mutational burden and EGFR/MAPK pathway activation as novel therapeutic targets in mEPC.